Cargando…
Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish
Pegylated liposomal doxorubicin (PLD) has been widely used to treat cancer. The adverse effects of PLD noted in clinical practice, especially hand-foot syndrome (HFS), are regarded as unique, and the management methods for them remain limited. This study was aimed at developing a feasible experiment...
Autores principales: | Chen, Yau-Hung, Lee, Ya-Ting, Wen, Chi-Chung, Chen, Yun-Chen, Chen, Yu-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085292/ https://www.ncbi.nlm.nih.gov/pubmed/25061318 http://dx.doi.org/10.2147/OTT.S63785 |
Ejemplares similares
-
Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin
por: Hu, Xiaolin, et al.
Publicado: (2021) -
Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study
por: Xiaozhe, Li, et al.
Publicado: (2022) -
Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients
por: Zheng, Yan-Fu, et al.
Publicado: (2021) -
Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin [Corrigendum]
Publicado: (2021) -
Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin
por: Nara, Katsuhiko, et al.
Publicado: (2023)